Meta-analysis of Risk Factors for Thrombocytopenia Related to Linezolid

Ge Mengjia,Chen Ken,Ma Qingbian,Yi Zhanmiao,Zhai Suodi

DOI: https://doi.org/10.3760/cma.j.issn.1008-5734.2016.06.002

2016-01-01

Abstract:Objective To evaluate the risk factors for thrombocytoPenia related to linezolid(LZD) comPrehensively. Methods The related databases were electronically searched for the case-control studies about risk factors for LZD-associated thrombocytoPenia from the incePtion to June 2016. The quality of the literature which was enrolled into the Meta-analysis evaluated by Newcastle-Ottawa Quality Assessment Scale (NOS),and then Meta-analysis was conducted using RevMan 5. 3 software. The results are Presented as odds risk( OR)and 95% confidence interval( CI). Results A total of 25 studies involving 4 279 Patients were entered, including 1 335 in the thrombocytoPenia grouP and 2 944 in the none thrombocytoPenia grouP. The NOS scores of all literature were greater than or equal to 7. The result of Meta-analysis showed that,the baseline Platelet count < 200 × 109 ∕ L(OR = 3. 64,95% CI:1. 60-8. 30,P =0. 002),body weight < 50 kg(OR = 2. 44,95% CI:1. 79-3. 34,P < 0. 001),creatinine clearance < 30 ml∕ min(OR = 1. 85,95% CI:1. 29-2. 67,P < 0. 001),duration of LZD theraPy > 14 days(OR = 1. 76, 95% CI:1. 17-2. 65,P = 0. 006)and age≥65 years(OR = 1. 54,95% CI:1. 03-2. 31,P = 0. 04)were identified as significant risk factors for LZD-associated thrombocytoPenia. Conclusion Current evidence shows that the severe damage to renal function,low baseline Platelet count,low body weight,long-term LZD administration and advanced age are risk factors of LZD-related thrombocytoPenia.